Scientists have pinpointed a specific protein that pancreatic cancer cells depend on for survival, a discovery that opens a new path for developing targeted treatments against the aggressive disease.
The research team found that the HSPE1 protein is crucial for the function of mitochondria, the energy centers of pancreatic cancer cells. This protein acts as a dual protector, helping mitochondria adapt to stress and also regulating the cancer cell's life cycle. When the researchers blocked the pathways controlled by HSPE1, they disrupted the mitochondria's ability to function, which triggered the self-destruction of the cancer cells. Critically, the study demonstrated that simultaneously targeting both pathways controlled by HSPE1 was significantly more effective at slowing tumor growth than inhibiting just one.
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, has a five-year survival rate of only 12%. It is notoriously resistant to standard treatments like chemotherapy and immunotherapy, creating an urgent need for new therapeutic strategies. The team identified the HSPE1 protein using a CRISPR-Cas9 genetic screening tool, which allowed them to scan thousands of genes to find those essential for cancer cell survival.
The findings lay a direct foundation for future drug development, identifying HSPE1 as a clear target for new combination therapies. The next steps involve further research to translate this discovery into potential drugs that can safely and effectively block this protein's activity in patients. While preliminary, this work offers a hopeful new direction in the fight against a cancer with limited treatment options, and future studies will explore if the same target is relevant in other aggressive cancers.